Floatz logo

gi-4000

mCRC

ImmunityBio, Inc.vaccinePhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the mCRC cohort.

View all 20

Same molecule, other indications

gi-4000 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →